Stocks in play: Oncolytics Biotech® Inc.
Announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. Oncolytics Biotech® Inc. shares T.ONC are trading down $0.03 at $1.39.
Read:
Agritech Industry Makes Strides in Ensuring Sustainable and Secure Food Supply
Tech Giants Drive AI Advancements as US Considers New Investment Rules for China
Private Sector Pushes Forward: Big Tech and AI Startups Thrive Amid Geopolitical Strife
Revolutionizing Enterprise Operations: Key Advancements in AI Infrastructure and Supplies
AI Adoption: Transforming the Future Economy with Boosted GDP and Productivity